Holen Sie sich die Stockscreener-App
114.44
0.12%
0.145
Schlusskurs vom Vortag:
$114.29
Offen:
$114.43
24-Stunden-Volumen:
293.77K
Relative Volume:
0.14
Marktkapitalisierung:
$6.69B
Einnahmen:
$76.81M
Nettoeinkommen (Verlust:
$-162.42M
KGV:
-38.27
EPS:
-2.99
Netto-Cashflow:
$-122.49M
1W Leistung:
+0.08%
1M Leistung:
+67.05%
6M Leistung:
+50.19%
1J Leistung:
+59.86%
1-Tages-Spanne:
$114.33
$114.45
1-Wochen-Bereich:
$114.23
$114.63
52-Wochen-Spanne:
$47.86
$114.80
Arcellx Inc Stock (ACLX) Company Profile
Firmenname
Arcellx Inc
Sektor
Branche
Telefon
240-327-0603
Adresse
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
114.44 | 6.68B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.70 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.82 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.88 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.61 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.63 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-22 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-07 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-04 | Bestätigt | Needham | Buy |
| 2023-12-19 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-10-30 | Eingeleitet | TD Cowen | Outperform |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-05-18 | Eingeleitet | Truist | Buy |
| 2023-04-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-14 | Eingeleitet | Stifel | Buy |
| 2023-02-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-13 | Fortgesetzt | BofA Securities | Buy |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-10-27 | Eingeleitet | Needham | Buy |
| 2022-07-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-03-01 | Eingeleitet | BofA Securities | Buy |
| 2022-03-01 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Arcellx Inc Aktie (ACLX) Neueste Nachrichten
Victory Capital Management Inc. Has $14.13 Million Stock Position in Arcellx, Inc. $ACLX - MarketBeat
Gilead’s US$7.8b Arcellx Deal Deepens Cell Therapy Diversification - simplywall.st
Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion - Finviz
Are ACLX, DBRG, AVO, CVGW Obtaining Fair Deals for their Shareholders? - Sahm
Arcellx set to report earnings amid $7.8B Gilead deal - Investing.com
American Century Companies Inc. Has $33.82 Million Position in Arcellx, Inc. $ACLX - MarketBeat
Blue Owl Capital Holdings LP Buys Shares of 26,823 Arcellx, Inc. $ACLX - MarketBeat
(ACLX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Gilead Sciences stock forecast for 2030: Can $7.8B Arcellx deal push GILD to $220 with no patent cliff until 2036? - Traders Union
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Top 2 Health Care Stocks That May Crash This QuarterArcellx (NASDAQ:ACLX), Anika Therapeutics (NASDAQ:ANIK) - Benzinga
Multiple Myeloma Market 2026: Gilead Sciences Acquires Arcellx for $7.8B to Control CAR-T Therapy - openPR.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Alkermes (ALKS) and Progyny (PGNY) - The Globe and Mail
Arcellx Inc stock hits all-time high at 114.27 USD - Investing.com Australia
Are ACLX, VRE, LSF Obtaining Fair Deals for their Shareholders? - Stock Titan
Gilead Sciences’ Yeztugo Revenue Is Set to Jump 400%: Here’s What Comes Next - TIKR.com
Arcellx (NASDAQ:ACLX) Hits New 52-Week HighStill a Buy? - MarketBeat
Arcellx Inc stock hits all-time high at 114.27 USD By Investing.com - Investing.com UK
Arcellx, Inc. (ACLX) Stock Analysis: Navigating Biotech’s Cutting Edge with Strategic Alliances - DirectorsTalk Interviews
Cowen Downgrades Arcellx, Inc. (ACLX) to Hold on March 2, 2026 - Meyka
ACLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance - Yahoo Finance
Arcellx stock rating cut to Hold by TD Cowen on Gilead deal - Investing.com India
Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement - The Globe and Mail
Arcellx President Sells $10M Worth of Shares After Acquisition Announcement - The Globe and Mail
TD Cowen Downgrades Arcellx to Hold From Buy - marketscreener.com
Citigroup Inc. Sells 13,427 Shares of Arcellx, Inc. $ACLX - MarketBeat
TD Asset Management Inc Buys 129,248 Shares of Arcellx, Inc. $ACLX - MarketBeat
Vanguard Group Inc. Sells 37,798 Shares of Arcellx, Inc. $ACLX - MarketBeat
Insider Selling: Arcellx (NASDAQ:ACLX) Insider Sells 89,916 Shares of Stock - MarketBeat
Arcellx CEO Elghandour sells $10.2 million in ACLX stock - Investing.com
Tax-withholding sale by Arcellx (NASDAQ: ACLX) director Elghandour - Stock Titan
Arcellx, Inc. Hits Day High with 77.43% Surge in Stock Price - Markets Mojo
E-Trade Financial (NASDAQ: ACLX) files Form 144 listing 164,548 RSU shares - Stock Titan
Taxation With Representation: Linklaters, Wilson Sonsini - Law360
Gilead Sciences Inc Stock Moved Up by 3.72% on Feb 27: What Investors Need To Know - TradingKey
Arcellx, Inc. Experiences Evaluation Revision Amid Strong Market Performance and Volatility - Markets Mojo
Arcellx (ACLX) Posts US$228.9m TTM Loss Testing Bullish Profitability Narratives - Sahm
Arcellx (NASDAQ:ACLX) Announces Earnings Results, Meets Estimates - MarketBeat
Arcellx, Inc. SEC 10-K Report - TradingView
Arcellx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ACLX SEC FilingsARCELLX INC 10-K, 10-Q, 8-K Forms - Stock Titan
Guggenheim Downgrades Arcellx to Neutral From Buy, Adjusts PT to $115 From $120 - marketscreener.com
Arcellx, Inc. Opens with a 77.48% Gain, Outperforming S&P 500's 0.69% Increase - Markets Mojo
Guggenheim downgrades Arcellx stock rating on Gilead acquisition By Investing.com - Investing.com Nigeria
Guggenheim downgrades Arcellx stock rating on Gilead acquisition - Investing.com India
Arcellx, Inc. Hits New 52-Week High of $114.26, Up 110% Yearly - Markets Mojo
Insider sells 19,675 shares — E-TRADE Financial (ACLX) files Form 144 - Stock Titan
Arcellx (ACLX) CFO reports tax-driven share sale after exercising 20,530 units - Stock Titan
Finanzdaten der Arcellx Inc-Aktie (ACLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):